Skip to main content
    I

    INmune Bio Inc (INMB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    -0.10 (-9.87%)

    Market Cap: $32.51M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    INmune Bio Inc (INMB) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect INmune Bio (INMB) to earn -$0.58 per share in the fiscal year ending Dec 31, 2026. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy133.3%
    Buy266.7%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    3

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$0.58
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$0.43
    EPS consensus, revenue $9.54M
    Next report
    Mar 29, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.58-$0.58 to -$0.581N/AN/A3
    Dec 31, 2027-$0.43-$0.43 to -$0.431$9.54M$3.90M to $15.18M2

    Quarterly Estimates

    The EPS consensus rises from -$0.20 for the quarter ending Dec 31, 2026 to -$0.18 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.20-$0.23 to -$0.156
    Mar 31, 2027-$0.18-$0.18 to -$0.181

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202620
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.43.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.58-$0.55-$0.55-$0.55-$0.43N/A
    Fiscal year ending Dec 31, 2027-$0.43-$0.49-$0.49-$0.53-$0.53N/A
    Quarter ending Mar 31, 2027-$0.18-$0.12-$0.12-$0.12-$0.12N/A

    Frequently Asked Questions About INMB

    What is the INMB stock forecast?

    Consensus analyst estimates put INmune Bio's EPS at -$0.58 for the fiscal year ending Dec 31, 2026. The consensus rating from 3 analysts is Buy.

    How do analysts rate INMB stock?

    Of 3 analysts covering INmune Bio, 1 rates it Strong Buy, 2 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from INMB next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.58, with estimates from -$0.58 to -$0.58 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.43, with estimates from -$0.43 to -$0.43 from 1 analyst.

    What revenue do analysts expect from INmune Bio next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $9.54M, with estimates from $3.90M to $15.18M.

    How many analysts cover INMB?

    3 analysts rate INmune Bio stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.